FluoGuide said a research grant connected to its work with Rigshospitalet in Copenhagen, Denmark, will help it set up a phase II trial for the company's FG001 radiopharmaceutical candidate in patients with less aggressive brain cancers.
The company said FG001, which is injected into the patient's vein prior to image-guided surgery, showed promise in a phase I/II trial.
The phase II trial is being planned together with Rigshospitalet's department of neurosurgery, which is already conducting the phase I/II trial in aggressive brain cancer. The trial is expected to begin in the second half of 2022.
The grant was awarded by Life Science Innovation North Denmark, which is running a Sundhedsteknologisk Service Program in collaboration with Danish Life Science Cluster.
